Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic
innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic …

This review describes the preclinical mechanisms that may underlie the increased
therapeutic benefit of combination therapy—with the N-methyl-d-aspartate receptor …

In Alzheimer's disease (AD), loss of cortical and hippocampal choline acetyltransferase
(ChAT) activity has been correlated with dementia severity and disease duration, and it …

A profound loss of cortical cholinergic innervation is a nearlyinvariant feature of advanced
Alzheimer's disease (AD). The temporal course of this lesion and its relationship to other …

In this review first we evaluate evidence on the role of the neurobiological alterations
induced by chronic ethanol consumption in the development of ethanol tolerance …

Evidence exists for both cholinergic and glutamatergic involvement in the etiology of
Alzheimer's disease. Acetylcholine (ACh), a neurotransmitter essential for processing …

The deficiency in cholinergic neurotransmission in Alzheimer's disease has led to the
development of cholinesterase inhibitors as the first-line treatment for symptoms of this …

Alzheimer's disease (AD) is a predominantly amnestic dementia that arises on a
neuropathological background of amyloid plaques (AP) and neurofibrillary tangles (NFT). A …

Accumulating epidemiological evidence implicates traumatic brain injury as a pathogenic
agent in the development of Alzheimer's disease (AD). Considering the increase in the …

Nicotine in patients with dementia of the Alzheimer type (DAT) producted a significant and
marked improvement in discriminative sensitivity and reaction times on a computerised test …